國立高雄大學圖資館 |

登入

回首頁

Immunotherapy against lung canceremerging opportunities and challenges /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Immunotherapy against lung canceredited by Shvetank Bhatt ... [et al.].
其他題名:	emerging opportunities and challenges /
其他作者:	Bhatt, Shvetank.
出版者:	Singapore :Springer Nature Singapore :2024.
面頁冊數:	xiv, 389 p. :ill., digital ;24 cm.
Contained By:	Springer Nature eBook
標題:	LungsCancer
電子資源:	https://doi.org/10.1007/978-981-99-7141-1
ISBN:	9789819971411$q(electronic bk.)

Immunotherapy against lung canceremerging opportunities and challenges /
Immunotherapy against lung canceremerging opportunities and challenges /[electronic resource] :edited by Shvetank Bhatt ... [et al.]. - Singapore :Springer Nature Singapore :2024. - xiv, 389 p. :ill., digital ;24 cm.

Chapter 1_An introduction to Lung cancer -- Chapter 2_Immunobiology of Lung cancer -- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy -- Chapter 4_Recent advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer -- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer -- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer -- Chapter 9_IDO and TGF-β inhibitors for the treatment of Lung cancer -- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer -- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer -- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer -- Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer -- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy -- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer -- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer -- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer -- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer.

This book provides insight into the various immunotherapeutic approaches for the treatment of lung cancers. The chapters of the book discuss the detailed mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive environment, and various vaccines for lung cancer. A chapter of the book explores the recent applications of the oncolytic virus in lung cancer treatment and discusses the potential and direction of oncolytic virus-based therapeutic vaccines. The chapter also elucidates the current understanding of the role of Toll-Like Receptors (TLRs) in tumor progression, and the recent progress in utilizing TLR agonists as potential therapeutic agents in lung cancer treatment. Towards the end, the book reviews the applications of stereotactic body radiation therapy (SBRT) and immunotherapy for the treatment of lung cancer. This book provides useful information to a range of audiences including clinical researchers working in the field of lung cancer, and undergraduate and postgraduate students from various disciplines such as pharmacy, microbiology, immunology, pharmacology, biotechnology, and health sciences.

ISBN: 9789819971411$q(electronic bk.)

Standard No.: 10.1007/978-981-99-7141-1doiSubjects--Topical Terms:

989845
Lungs
--Cancer

LC Class. No.: RC280.L8

Dewey Class. No.: 616.994206

Immunotherapy against lung canceremerging opportunities and challenges /
LDR:03738nmm a2200325 a 4500 001 676147
003 DE-He213
005 20240923084718.0
006 m d
007 cr nn 008maaau
008 250825s2024 si s 0 eng d
020 $a 9789819971411$q(electronic bk.)
020 $a 9789819971404$q(paper)
024 7 $a 10.1007/978-981-99-7141-1 $2 doi
035 $a 978-981-99-7141-1
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.L8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994206 $2 23
090 $a RC280.L8 $b I33 2024
245 0 0 $a Immunotherapy against lung cancer $h [electronic resource] : $b emerging opportunities and challenges / $c edited by Shvetank Bhatt ... [et al.].
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Springer, $c 2024.
300 $a xiv, 389 p. : $b ill., digital ; $c 24 cm.
505 0 $a Chapter 1_An introduction to Lung cancer -- Chapter 2_Immunobiology of Lung cancer -- Chapter 3_Evolution of Lung cancer treatment from classical chemotherapy to advanced immunotherapy -- Chapter 4_Recent advances in the immunotherapy of Lung cancer -- Chapter 5_PD-1/PD-L1 inhibitors for the treatment of Lung cancer -- Chapter 6_CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 7_Adoptive T cell therapy for the treatment of Lung cancer -- Chapter 8_LAG-3 inhibitors for the treatment of Lung cancer -- Chapter 9_IDO and TGF-β inhibitors for the treatment of Lung cancer -- Chapter 10_OX40 and CD40 agonists for the treatment of Lung cancer -- Chapter 11_ICOS and GITR agonists for the treatment of Lung cancer -- Chapter 12_Vaccines and oncolytic virus for the treatment of Lung cancer -- Chapter 13_Targeting Toll-like receptors for the treatment of Lung cancer -- Chapter 14_Current and future perspectives of combining chemotherapy and stereotactic body radiation therapy with immunotherapy -- Chapter 15_Synergistic potential of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors for the treatment of Lung cancer -- Chapter 16_Synergistic potential of antigen-specific vaccines and immunomodulatory agents for the treatment of Lung cancer -- Chapter 17_Important biomarkers for better evaluation of checkpoint inhibitors and another immunotherapy in Lung cancer -- Chapter 18_Insight on the clinical trials of immunotherapy for the treatment of Lung cancer -- Chapter 19_Future perspectives of the Cancer Immunotherapy for the treatment of Lung cancer.
520 $a This book provides insight into the various immunotherapeutic approaches for the treatment of lung cancers. The chapters of the book discuss the detailed mechanisms of checkpoint inhibitors, co-stimulatory molecules, drugs working in the immunosuppressive environment, and various vaccines for lung cancer. A chapter of the book explores the recent applications of the oncolytic virus in lung cancer treatment and discusses the potential and direction of oncolytic virus-based therapeutic vaccines. The chapter also elucidates the current understanding of the role of Toll-Like Receptors (TLRs) in tumor progression, and the recent progress in utilizing TLR agonists as potential therapeutic agents in lung cancer treatment. Towards the end, the book reviews the applications of stereotactic body radiation therapy (SBRT) and immunotherapy for the treatment of lung cancer. This book provides useful information to a range of audiences including clinical researchers working in the field of lung cancer, and undergraduate and postgraduate students from various disciplines such as pharmacy, microbiology, immunology, pharmacology, biotechnology, and health sciences.
650 0 $a Lungs $x Cancer $x Immunotherapy. $3 989845
650 1 4 $a Cancer Therapy. $3 915060
650 2 4 $a Tumour Immunology. $3 921116
700 1 $a Bhatt, Shvetank. $3 969034
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-99-7141-1
950 $a Medicine (SpringerNature-11650)